Use of T-SPOT.TB for the diagnosis of unconventional pleural tuberculosis is superior to ADA in high prevalence areas: a prospective analysis of 601 cases

Table 5 Performance outcomes of a bioclinical score for ADA and T.SPOT

Score (non: TPE)	Assay (cut-off value ^a)	Sensitivity	Specificity	PPV	NPV	Accuracy	§X²	§P value	¶X²	¶P value
	ADA(40)	23.5	96.9	80.0	70.5	71.4	5.82	0.016	0.80	0.370
0 (32:17)	PB T.SPOT(24)	76.5	62.5	52.0	83.3	67.3
	PF T.SPOT(466)	76.5	84.4	72.2	87.1	81.6
2	ADA(40)	51.0	94.4	92.9	57.1	68.7	21.42	< 0.001	7.26	0.006
	PB T.SPOT(24)	79.4	64.5	76.4	68.3	73.3
/3/5 (107:155)	PF T.SPOT(466)	76.1	80.4	84.9	69.9	77.9
6/8/9	ADA(40)	73.2	86.7	95.9	43.3	75.8	10.26	0.001	0.14	0.705
(30:127)	PB T.SPOT(24)	93.7	93.3	98.3	77.8	93.6
	PF T.SPOT(466)	89.8	90.0	97.4	67.5	89.8
	ADA(40)	81.6	80.0	98.8	18.2	81.6	0.04	0.840	0	> 0.999
11 (5:98)	PB T.SPOT(24)	85.7	60.0	97.7	17.6	84.5
	PF T.SPOT(466)	80.6	80.0	98.8	17.4	79.0

ADA adenosine deaminase, BMI body mass index, TPE tuberculous pleural effusion, NPV negative predictive value, PPV positive predictive value
Age < 45 yrs., male and BMI < 22 scored 6, 3, 2 points, respectively
§Comparisons were performed for sensitivity between ADA and PF T.SPOT using chi-square test
¶ Comparisons were performed for specificity between ADA and PF T.SPOT using chi-square test
^a Values are expressed as IU/L for ADA, and as SFCs/10⁶ mononuclear cells for T-SPOT.Data are presented as percentage

ISSN: 1471-2334